Unassociated Document
FORM 10-QSB

U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

(X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2006

Commission file number 001-10647 

PRECISION OPTICS CORPORATION, INC.
(Exact name of small business issuer as specified in its charter)
 
 Massachusetts 
  
 04-2795294
 (State or other jurisdiction of 
  
 (I.R.S. Employer
 incorporation or organization) 
  
 Identification No.)
 
22 East Broadway, Gardner, Massachusetts 01440-3338
(Address of principal executive offices) (Zip Code)

(978) 630-1800
(Issuer's telephone number, including area code)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes (X) No ( )

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act).

Yes ( ) No (X)

The number of shares outstanding of issuer's common stock, par value $.01 per share, at November 1, 2006 was 15,458,212 shares.

Transitional Small Business Disclosure Format (check one):
Yes ( ) No (X)
 

 Item 1
 
PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(UNAUDITED) 
ASSETS
 
             
CURRENT ASSETS
    
September 30, 2006 
    
June 30, 2006 
  
Cash and Cash Equivalents
  
$
1,274,979
  
$
2,030,428
  
Accounts Receivable, net
    
342,913
    
381,097
  
Inventories, net
    
500,335
    
445,802
  
Prepaid Expenses
    
44,547
    
45,912
  
Total Current Assets
    
2,162,774
    
2,903,239
  
PROPERTY AND EQUIPMENT
              
Machinery and Equipment
    
3,538,217
    
3,513,736
  
Leasehold Improvements
    
553,595
    
553,596
  
Furniture and Fixtures
    
93,545
    
93,545
  
Vehicles
    
42,343
    
42,343
  
     
4,227,700
    
4,203,220
  
               
Less: Accumulated Depreciation
    
(4,139,290
)
  
(4,127,287
)
Net Property and Equipment
    
88,410
    
75,933
  
OTHER ASSETS
              
Cash surrender value of life insurance policies
    
13,246
    
13,246
  
Patents, net
    
275,572
    
236,115
  
 Total Other Assets
    
288,818
    
249,361
  
TOTAL ASSETS
  
$
2,540,002
  
$
3,228,533
  
 
LIABILITIES AND STOCKHOLDERS' EQUITY
 
CURRENT LIABILITIES
           
Accounts Payable
  
$
286,570
  
$
218,658
  
Accrued Employee Compensation
    
163,063
    
227,892
  
Accrued Professional Services
    
41,750
    
90,000
  
Accrued Warranty Expense
    
50,000
    
50,000
  
Other Accrued Liabilities
    
4,008
    
2,086
  
 Total Current Liabilities
    
545,391
    
588,636
  
STOCKHOLDERS' EQUITY
              
Common Stock, $.01 par value-
Authorized -- 20,000,000 shares
Issued and Outstanding -15,458,212 shares
at September 30, 2006 and at June 30, 2006
    
154,582
    
154,582
  
Additional Paid-in Capital
    
34,772,765
    
34,729,873
  
Accumulated Deficit
    
(32,932,736
)
  
(32,244,558
)
Total Stockholders' Equity
    
1,994,611
    
2,639,897
  
 
              
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
  
$
2,540,002
  
$
3,228,533
  
 
2
 
PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE MONTHS ENDED
SEPTEMBER 30, 2006 AND SEPTEMBER 30, 2005
(UNAUDITED)
 
   
Three Months
Ended September 30, 
  
   
2006
  
2005
  
REVENUES
  
$
474,154
  
$
419,582
  
               
COST OF GOODS SOLD
    
485,925
    
521,501
  
               
Gross Loss
    
(11,771
)
  
(101,919
)
               
RESEARCH and DEVELOPMENT EXPENSES
    
207,824
    
208,111
  
               
SELLING, GENERAL and ADMINISTRATIVE EXPENSES
    
483,787
    
424,688
  
               
GAIN ON SALE OF FIXED ASSETS    
-
    
(165,700
)
               
 Total Operating Expenses
    
691,611
    
467,099
  
               
Operating Loss
    
(703,382
)
  
(569,018
)
               
INTEREST INCOME
    
15,203
    
9,147
  
               
Net Loss
  
$
(688,179
)
$
(559,871
)
               
Basic and Diluted Loss Per Share  
$
(0.04
)
$
(0.08
)
               
               
Weighted Average Common Shares Outstanding -    
15,458,212
    
7,008,212
  
Basic and Diluted
              
 
3
 
PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED
SEPTEMBER 30, 2006 AND 2005
(UNAUDITED)
 
   
Three Months
Ended September 30, 
  
   
2006
  
 2005
  
CASH FLOWS FROM OPERATING ACTIVITIES:
           
Net Loss 
   $ (688,179 )
$
(559,871
)
Adjustments to Reconcile Net Loss to Net Cash
              
 Used In Operating Activities -
              
 Depreciation and Amortization
    
12,003
    
41,382
  
 Gain on Disposal of Asset
    
-
 
  
(165,700
)
Stock-based compensation expense
    
58,353
    
-
  
 Changes in Operating Assets and Liabilities-
              
 Accounts Receivable
    
38,184
    
(33,571
)
 Inventories
    
(54,533
)
  
1,772
  
 Prepaid Expenses
    
1,366
    
(33,476
)
 Accounts Payable
    
67,912
    
75,103
  
 Other Accrued Expenses
    
(111,156
)
  
(3,769
)
Net Cash Used In Operating Activities
    
(676,050
)
  
(678,130
)
               
CASH FLOWS FROM INVESTING ACTIVITIES:
              
Purchases of Property and Equipment
    
(24,481
)
  
(8,017
)
Proceeds from Disposal of Asset
    
-
    
162,000
  
Increase in Other Assets
    
(39,458
)
  
(15,228
)
Net Cash Provided By (Used In) Investing Activities
    
(63,939
)
  
138,755
  
               
CASH FLOWS FROM FINANCING ACTIVITIES:
              
Payment of Offering Costs
    
(15,460
)
  
-
  
Net Cash Provided By Financing Activities
    
(15,460
)
  
-
  
             
NET DECREASE IN CASH AND CASH EQUIVALENTS
    
(755,449
)
  
(539,375
)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD
    
2,030,428
    
2,171,693
  
               
CASH AND CASH EQUIVALENTS AT END OF PERIOD
  
$
1,274,979
  
$
1,632,318
  
               
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
              
 Cash Paid for-
              
 Interest
  
$
-
  
$
-
  
 Income Taxes
  
$
912
  
$
912
  
 
4
 
        
PRECISION OPTICS CORPORATION, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1.  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation and Operations
 
The accompanying consolidated financial statements include the accounts of Precision Optics Corporation, Inc. and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
 
These consolidated financial statements have been prepared by the Company, without audit, and reflect normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the results of the first quarter of the Company's fiscal year 2007. These consolidated financial statements do not include all disclosures associated with annual consolidated financial statements and, accordingly, should be read in conjunction with footnotes contained in the Company's consolidated financial statements for the year ended June 30, 2006 together with the Report of Independent Registered Public Accounting Firm filed under cover of the Company's 2006 Annual Report on Form 10-KSB.
 
The Company has incurred significant operating losses during the last ten fiscal years. This trend was primarily the result of the loss of several significant customers, completion of several large nonrecurring government contracts, and operating losses and provision for asset impairment, restructuring, and inventory write-downs associated with the downturn in demand for optical filters used in telecommunications systems. In fiscal 1998, the Company began making significant investments in research and development and capital purchases for new products. In August 1999 and March 2000, the Company raised gross proceeds of approximately $16 million of additional cash through the issuance of common stock. In July 2004, the Company completed a rights offering to stockholders by issuing 5,256,159 shares of common stock. Net cash proceeds to the Company (after offering costs of $222,175) were $5,033,984. In April 2006 the Company completed a private placement, issuing 8,450,000 shares of common stock. Net cash proceeds to the Company (after offering costs of $49,725) were $2,062,775.
 
In the past five fiscal years, the Company has implemented a number of restructuring and cost saving measures in an effort to align costs with revenues and strengthen financial performance. Full-time employee headcount has been reduced from 78 at June 30, 2001 to 30 at September 30, 2006. The Company has discontinued the development and manufacturing of telecommunications products, canceled the lease on its Optical Thin Films Technology Center, and written down and/or sold certain property, equipment and inventories invested in its telecommunications business. The Company will continue its review of other expense areas to determine where additional reductions in discretionary spending can be achieved.
 
5
 
The Company’s current sources of liquidity consist of its cash and cash equivalents and accounts receivable. At September 30, 2006 the Company had $1,274,979 in cash and cash equivalents and $342,913 in accounts receivable.
 
The Company expects its recent pattern of quarter-to-quarter revenue fluctuations to continue, due to the uncertain timing of individual orders and their size in relation to total revenues. The Company remains confident in the value of its technology and expertise in medical applications and elsewhere. In addition, despite strict controls on R&D spending, the Company continues to move forward with new products and technical innovations.
 
During the past year, the introduction of several new products, along with new and on-going customer relationships, have resulted in significant revenue growth. The Company believes that with continued promotion, these opportunities will continue the general trend of increasing revenues.
 
Use of Estimates
 
The preparation of these consolidated financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
 
Loss Per Share
Basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. For the three months ended September 30, 2006 and 2005, the effect of stock options and warrants was antidilutive; therefore, they were not included in the computation of diluted loss per share. The number of shares issuable upon the exercise of outstanding stock options and warrants that were excluded from the computation as their effect would be antidilutive were approximately 2,492,583 and 1,316,783 for the three months ended September 30, 2006 and 2005, respectively.

Revenue Recognition
 
In December 2003, the Securities and Exchange Commission issued Staff Accounting Bulletin (“SAB”) No. 104 which establishes guidance in applying generally accepted accounting principles to revenue recognition in financial statements and was effective for the Company’s fiscal year 2004. SAB No. 104 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services rendered; (3) the price to the buyer is fixed and determinable; and (4) collectibility is reasonably assured. The Company’s shipping terms are customarily FOB shipping point. The Company’s revenue recognition practices comply with the guidance in the bulletin.
 
6
 
The sales price of products and services sold is fixed and determinable after receipt and acceptance of a customer’s purchase order or properly executed sales contract, typically before any work is performed. Management reviews each customer purchase order or sales contract to determine that the work to be performed is specified and there are no unusual terms and conditions which would raise questions as to whether the sales price is fixed or determinable. The Company assesses credit worthiness of customers based upon prior history with the customer and assessment of financial condition. Accounts receivable are stated at the amount management expects to collect from outstanding balances. An allowance for doubtful accounts is provided for that portion of accounts receivable considered to be uncollectible, based upon historical experience and management’s evaluation of outstanding accounts receivable at the end of the year. Bad debts are written off against the allowance when identified.
 
The Company’s revenue transactions typically do not contain multiple deliverable elements for future performance obligations to customers, other than a standard one-year warranty on materials and workmanship, the estimated costs for which are provided for at the time revenue is recognized.

Revenues for industrial and medical products sold in the normal course of business are recognized upon shipment when delivery terms are FOB shipping point and all other revenue recognition criteria have been met. Services that the Company provides to customers consist of repairs and engineering design and development. Recognition of service revenue occurs (assuming all other revenue recognition criteria have been met) upon delivery to the customer of the repaired product. Gross shipping charges reimbursable from customers, to deliver product, are insignificant and are included in Revenues, while shipping costs are shown in Selling, General and Administrative Expenses section of the Consolidated Statement of Operations.

Income Taxes
 
Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

In assessing the likelihood of utilization of existing deferred tax assets, management has considered historical results of operations and the current operating environment.
 
Recent Accounting Pronouncements
 

In July 2006, the FASB issued FASB Interpretation No. 48 "Accounting for Uncertainty in Income Taxes" ("FIN48"). FIN 48 is an interpretation of FASB Statement No. 109. "Accounting for Income Taxes," and it seeks to reduce the diversity in practice associated with certain aspects of measurement and recognition in accounting for income taxes. In addition, FIN 48 requires expanded disclosure with respect to the uncertainty in income taxes and is required to be adopted for fiscal years beginning after December 15, 2006. The Company is currently evaluating the impact, if any, that FIN 48 will have on its financial statements.
 
7

In September 2006, the FASB issued Statement of Financial Accounting Standards No. 157 "Fair Value Measurements", ("FAS 157"). FAS 157 defines fair value, establishes a framework for measuring fair value, and expands disclosure requirements regarding fair value measurement. FAS 157 is effective for the Company beginning July 1, 2008. The Company is currently reviewing the Statement to determine the impact and materiality of its adoption to the Company.

In September 2006, the SEC issued Staff Accounting Bulletin No. 108 ("SAB 108"), Considering the Effects of Prior Year Misstatements When Quantifying Misstatements in Current Year Financial Statements, providing guidance on quantifying financial statement misstatement and implementation when first applying this guidance. Under SAB No.108, companies should evaluate a misstatement based on its impact on the current year income statement, as well as the cumulative effect of correcting such misstatements that existed in prior years still existing in the current year's ending balance sheet. SAB 108 is effective for fiscal years ending after November 15, 2006.  The Company is currently evaluating the impact, if any, that SAB No. 108 will have on its financial statements.
 
8
 
2. INVENTORIES
 
Inventories are stated at the lower of cost (first-in, first-out) or market and consist of the following:
 
   
September 30, 2006
  
June 30, 2006
  
Raw Materials
  
$
316,976
  
$
251,725
  
Work-In-Progress
    
125,706
    
114,786
  
Finished Goods
    
57,653
    
79,291
  
Total Inventories
  
$
500,335
  
$
445,802
  
 
3.  STOCK-BASED COMPENSATION

On July 1, 2006, the Company adopted Statement of Financial Accounting Standards No. 123(R) (SFAS 123(R)) “Accounting for Stock-Based Compensation”, which requires the measurement and recognition of all compensation costs for all stock based awards made to employees and the Board of Directors based upon fair value over the requisite service period for awards expected to vest. Prior to adoption, the Company accounted for stock options under the intrinsic value method set in accordance with Accounting Principles Board Opinion No. 25, “Accounting for Stock Issued to Employees,” and related interpretations, and provided the required pro forma disclosures prescribed by SFAS No. 123, “Accounting for Share-based Compensation”, as amended.
 
SFAS 123(R) requires the Company to estimate the fair value of share-based awards on the date of grant using an option pricing model. The Company adopted SFAS 123(R) using the modified prospective transition method which requires the application of the accounting standard starting July 1, 2006, the first day of Company’s fiscal year 2007. Prior period information will not be restated to reflect the fair value method of expensing share-based awards.
 
Stock- based compensation costs recognized for the three month period ended September 30, 2006, included compensation costs for awards granted prior to, but not yet vested as of July 1, 2006 (adoption date), as well as any new grants issued after July 1, 2006. Total costs recognized during the three month period ended September 30, 2006 amounted to approximately $58,000, and are included in selling, general and administrative expenses in the accompanying consolidated statements of operations. No compensation has been capitalized because such amount would have been immaterial. There was no income tax benefit related to such compensation for the three months ended September 30, 2006, as the Company is currently in a loss position. Total amount of options granted during the three months ended September 30, 2006 were 225,000.
 
As of September 30, 2006, the unrecognized compensation costs related to options vesting will be primarily recognized over a period of approximately 5 years:
 
OPTIONS
  
2007
  
2008
  
2009
  
2010
  
2011
  
Total
  
                           
Compensation Expense
    
134,452
    
98,150
    
84,720
    
21,805
    
21,805
    
360,932
  
 
The Company had previously adopted the provisions of SFAS No. 123, “Accounting for Share-based Compensation,” as amended by SFAS No. 148, “Accounting for Share-based Compensation—Transition and Disclosure,” through disclosure only. The following table illustrates the effect on net income and earnings per share for the three months ended September 30, 2005 as if the Company had applied the fair value recognition provisions of SFAS No. 123 to share-based employee awards.
 
9
 
 
  
Three Months Ended September 30, 2005
  
Net loss as reported
  
$
(559,871
)
Add: Employee compensation expense for share options included in reported net income, net of income taxes
    
—
  
Less: Total employee compensation expense for share options determined under the fair value method, net of income taxes
    
(107,272
)
Pro forma net income
  
$
(667,143
)
Earnings per share:
      
Basic and diluted—as reported
  
$
0.08
  
Basic and diluted—pro forma
  
$
0.10
  
 
Upon adoption of SFAS 123(R), in accordance with Staff Accounting Bulletin No. 107, the Company selected the Black-Scholes option pricing model as the most appropriate method for determining the estimated fair value for the stock awards. The Black-Scholes method of valuation requires several assumptions: (1) the expected term of the stock award, (2) the expected future stock volatility over the expected term and (3) risk-free interest rate. The expected term represents the expected period of time the Company believes the options will be outstanding based on historical information. Estimates of expected future stock price volatility are based on the historic volatility of the Company’s common stock and the risk free interest rate is based on the U.S. Zero-Bond rate. The Company utilizes a forfeiture rate based on an analysis of the Company's actual experience. The fair value of options at date of grant was estimated with the following assumptions:
 
 
  
Three Months Ended
  
 
  
September 30, 2006
  
September 30, 2005
  
Assumptions:              
Option life
    
5.3 years
    
5.3 years
  
Risk-free interest rate
    
5.00%
 
  
3.84%
 
Stock volatility
    
108%
 
  
107%
 
Dividend yield
    
-0-
    
-0-
  
Weighted average fair value of grants
  
 
$0.27
  
 
$0.60
  
 
Stock Option and Other Compensation Plans:
 
Effective July 1, 2006, the Company adopted SFAS 123(R) using the modified prospective method to account for share-based payments to employees and the Company’s Board of Directors. The type of share-based payments currently utilized by the Company is stock options.
 
The Company has various stock option and other compensation plans for directors, officers, and employees. The Company has the following stock option plan outstanding as of September 30, 2006: Amended and Restated 1997 Incentive Plan. Vesting periods are at the discretion of the Board of Directors and typically average five years. Options under these plans are granted at fair market value and have a term of ten years from the date of grant.
 
10
 
The following tables summarize stock option activity during the first three months of fiscal year 2007:
 
 
  
Options Outstanding
  
 
  
Number of
Shares
  
Weighted Average
Exercise Price
  
Weighted Average
Contractual Life
  
 
  
 
  
 
  
 
  
Outstanding at June 30, 2006
    
2,277,583
  
$
0.66
      
Grants
    
225,000
    
0.27
      
Exercises
    
—
            
Cancellations
    
(10,000
 )  
0.55
      
Outstanding at September 30, 2006
    
2,492,583
  
$
0.63
  
$
9.64 years
  
                     
 
Information related to the stock options outstanding as of September 30, 2006 is as follows:
 
Range of Exercise Prices
  
Number of
Shares
  
Weighted-Average
Remaining
Contractual
Life (years)
  
Weighted-Average
Exercise Price
  
Exercisable
Number of
Shares
  
Exercisable
Weighted-Average
Exercise Price
  
$.25
    
125,000
    
9.96
  
$
0.25
    
20,835
  
$
0.25
  
$.30
    
100,000
    
9.89
    
0.30
    
-
    
0.30
  
$0.46
    
20,000
    
9.16
    
0.46
    
20,000
    
0.46
  
$0.55
    
1,313,583
    
9.61
    
0.55
    
553,512
    
0.55
  
$0.83
    
934,000
    
8.81
    
0.83
    
280,200
    
0.83
  
$0.25-$0.83
    
2,492,583
    
9.64
  
$
0.63
    
874,574
  
$
0.63
  
 
The aggregate intrinsic value of the Company’s “in-the-money” outstanding and exercisable options as of September 30, 2006 was $18,750 and $3,125, respectively.

On June 13, 2005 the Company issued options to purchase 934,000 shares (“Performance Options”) of common stock at an exercise price of $0.83 per share.   At the date of issuance, 30% of the options vested immediately, and the vesting of the remaining options is subject to achievement of certain financial milestones by the Company. 

On May 9, 2006, the Company’s Board of Directors approved the repricing of certain stock options held by employees and certain members of the Board of Directors. The new exercise price per share of common stock subject to such options (“Repriced Options”) was set at $0.55. The new exercise price per share applies to all stock options with an original exercise price above $0.55 per share, other than an option to purchase 560,400 shares of common stock held by Joseph Forkey and an option to purchase 373,600 shares of common stock held by Richard Forkey. Approximately 382,783 options were affected in the repricing.

According to Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees," the Performance Options and Repriced Options were subject to variable accounting until the awards are exercised, forfeited, or expire unexercised, which includes periodic measurement of compensation expense based on the intrinsic value of the options. The compensation cost, if any, was recognized and adjusted quarterly for vested options or ratably over the vesting period for unvested options. No compensation expense related to these stock options was reflected in the net loss for the quarter ended September 30, 2005 as all options granted had an exercise price greater than the market value of the underlying common stock as of September 30, 2005. Upon the adoption of SFAS No. 123('R), these options are no longer subject to variable accounting.  Compensation related to these options is included in the amounts disclosed above for the quarter ended September 30, 2006.
 
4.  Sale of Equipment

In June 2005 the Company received an $18,000 deposit towards the sale of equipment previously used in its discontinued telecommunications business and in July 2005 recognized the sale of this equipment for $180,000, resulting in a gain of $165,700 in the quarter ending September 30, 2005.
 
11
 
Item 2

PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES

Management's Discussion and Analysis of Financial
Condition and Results of Operations

Important Factors Regarding Forward-Looking Statements
 
When used in this discussion, the words “believes”, “anticipates”, “intends to”, and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties which could cause actual results to differ materially from those projected. These risks and uncertainties, many of which are not within the Company’s control, include, but are not limited to, the uncertainty and timing of the successful development of the Company’s new products, the risks associated with reliance on a few key customers; the Company’s ability to attract and retain personnel with the necessary scientific and technical skills, the timing and completion of significant orders; the timing and amount of the Company’s research and development expenditures; the timing and level of market acceptance of customers’ products for which the Company supplies components; performance of the Company’s vendors; the ability of the Company to control costs associated with performance under fixed price contracts; and the continued availability to the Company of essential supplies, materials and services. Readers are cautioned not to place undue reliance on these forward looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Overview

Precision Optics Corporation, a developer and manufacturer of advanced optical instruments since 1982, designs and produces high-quality optical thin film coatings, micro-optics, medical instruments, and other advanced optical systems. The Company’s medical instrumentation line includes laparoscopes, arthroscopes and endocouplers and a world-class product line of 3-D endoscopes for use in minimally invasive surgical procedures.

The Company is currently developing specialty instruments incorporating its patent-pending LENSLOCK TM technology which is designed to provide lower cost, easier reparability and enhanced durability. The Company is also aggressively pursuing ultra-small instruments (some with lenses less than one millimeter in diameter) utilizing patent-pending micro-precision TM lens technology. The Company is also exploring new initiatives in single-molecule technology and nanotechnology for biomedical and other applications.

Precision Optics Corporation is certified to the ISO 9001 and ISO 13485 Quality Standards and complies with the FDA Good Manufacturing Practices and the European Union Medical Device Directive for CE marking of its medical products. The Company’s internet website is www.poci.com.

The areas in which the Company does business are highly competitive and include both foreign and domestic competitors. Many of the Company’s competitors are larger and have substantially greater resources than the Company. Furthermore, other domestic or foreign companies, some with greater financial resources than the Company, may seek to produce products or services that compete with those of the Company. The Company routinely outsources specialized production efforts as required, both domestic and off-shore to obtain the most cost effective production. Over the years, the Company has achieved extensive experience with other optical specialists worldwide.
 
12
 
Since the 1990’s the Company has maintained a Hong Kong subsidiary to support business and quality control activities as required throughout Asia. The Company believes that the cost savings from such production is essential to the Company’s ability to compete on a price basis in the medical products area particularly and to the Company’s profitability in general.

The Company believes that competition for sales of its medical products and services, which have been principally sold to original equipment manufacturer (OEM) customers, is based on performance and other technical features, as well as other factors, such as scheduling and reliability, in addition to competitive price.

The Company believes that its future success depends to a large degree on its ability to continue to conceive and to develop new optical products and services and to enhance the performance characteristics and methods of manufacture of existing products. Accordingly, it expects to continue to pursue product-related design and development contracts with customers and to invest its own funds on research and development, to the extent funds are available.

Growth Trends and Critical Factors

Over the past few years new product and technology development has undergone significant changes in shifting the emphasis of R&D efforts from the development of underlying technologies to the market exploitation realizing new sales in the applications of these new technologies. These have already been realized to some degree in a number of areas. Over the past 2 - 3 years these developments have produced revenues from new microprecision™ lens products and new LenslockTM endoscopes. Recent initiatives in the area of microprecision™ lenses address specific customer opportunities in 3 or 4 different medical specialty applications. Similarly, in endoscope technologies we continue new product offerings in application of our LenslockTM product line with over 150 such instruments produced and sold in the past year. Other instruments with possible volume production include our new video ophthalmoscope which was developed and shipped in the past 18 months.

Our capabilities with very small high precision lenses have begun to realize new markets for our core competencies in medical optical systems design, development and production. Among our specialties in fiber optics, we have been the pre-eminent supplier of micro endocouplers for the past decade, used to “read out”, visually or electronically, ½ mm fiber optic image bundles. Recent customer requests for custom medical systems require special applications of the Company’s proprietary fiber optic techniques and autoclavable instrumentation development and production experience.

In our LenslockTM line, having now demonstrated commercial production viability for the 2.7mm ENT scope, we expect to have our new 4 mm arthroscope and sinuscope instruments ready to be introduced by January, 2007.
 
13
 
Clearly, there has been a major change in our Company over the past year. Recently developed technologies are now being realized as production or pre-production hardware. Going forward, our expectations are aimed at applied development for revenue bearing products. Some examples beyond the new instruments mentioned above include our lens development for a new Night Vision system which is undergoing customer evaluation as well as a new line of industrial filter thin film coatings, which are nearing completion, for a specific customer.

Sales and Marketing Development

Within the past six months we have added significant new resources for the Company with the addition of a Director of Marketing with special experience in broad market initiatives especially in the medical field. Together with our existing sales and marketing staff, this team has already begun a number of efforts to strengthen our market presence. This has included a newly designed website (www.poci.com, expected to go live on or about 11/20/06), and a much more comprehensive view of trade show opportunities. This ability, coupled with the recently renewed efforts for select key trade show attendance by our Chief Scientific Officer, our CEO as well as our overall sales and marketing staff now allows a much greater opportunity to reach and follow up a broader customer base than we have heretofore been able to achieve. A number of new opportunities are already leading to customer discussions for prospects for our new technologies including, LenslockTM, micro precisionTM, and custom applications of our core optical capabilities. This includes renewed interest in some of our well-developed products such as our “classic” autoclavable endoscopes, and endocouplers, as well as new applications with our micro (fiberoptic) endoscopes.

The Company places great emphasis in bringing new products to near term sales opportunities with prospects for long-term customer relationships.


Critical Accounting Policies and Estimates

General

Management’s discussion and analysis of financial condition and results of operations are based upon the Company’s consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The preparation of these consolidated financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

The Company believes that the following critical accounting policies affect its more significant judgments and estimates used in the preparation of its consolidated financial statements.

Revenue Recognition

The Company recognizes revenue in accordance with U.S. GAAP and the Securities and Exchange Commission Staff Accounting Bulletin (“SAB”) No. 104 Revenue Recognition in Financial Statements. SAB No. 104 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services rendered; (3) the price to the buyer is fixed and determinable; and (4) collectibility is reasonably assured. The Company assesses credit worthiness of customers based upon prior history with the customer and assessment of financial condition. The Company’s shipping terms are customarily FOB shipping point.
 
14
 
Bad Debt

The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. Allowances for doubtful accounts are established based upon review of specific account balances and historical experience. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to make future payments, additional allowances may be required.

Inventories

The Company provides for estimated obsolescence on unmarketable inventory based upon assumptions about future demand and market conditions. If actual demand and market conditions are less favorable than those projected by management, additional inventory write downs may be required. Inventory, once written down, is not subsequently written back up, as these adjustments are considered permanent adjustments to the carrying value of the inventory.

Impairment of Long-Lived Assets and Long-Lived Assets to be Disposed of

The Company accounts for impairment of long-lived assets in accordance with SFAS No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets. This statement requires that long-lived assets and certain identifiable intangibles be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to undiscounted future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets to be disposed of through sale are reported at the lower of the carrying amount or fair value less estimated costs to sell.

Income Taxes
 
Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
 
In assessing the likelihood of utilization of existing deferred tax assets, management has considered historical results of operations and the current operating environment.
 
15
 
Stock-Based Compensation
 
Effective July 1, 2006, the Company adopted the fair-value recognition provisions of Statement of Financial Accounting Standards No. 123 revised, "Accounting for Stock-Based Compensation" (SFAS No. 123(R)) to expense stock-based compensation.
 
Results of Operations

Total revenues for the quarter ended September 30, 2006 (the first quarter of fiscal year 2007) increased by approximately $55,000 or 13% from the same period in the prior year. The increase was due primarily to higher sales of medical products including micro-precisionTM optics and traditional LenslockTM endoscopes.

Revenues from the Company’s largest customers, as a percentage of total revenues for the three months ended September 30, 2006 and 2005, were as follows:

   
2006
  
2005
  
Customer A
    
38
    
15
  
Customer B
    
10
    
15
  
All Others
    
52
    
70
  
     
100
%
  
100
%

No other customer accounted for more than 10% of the Company’s revenues during those periods.

At September 30, 2006, receivables from the Company’s two largest customers were approximately 29% and 28%, respectively, of the total net accounts receivable. At June 30, 2006, receivables from the Company’s three largest customers were approximately 17%, 14%, and 14%, respectively, of the total net accounts receivable. No other customer accounted for more than 10% of the Company’s receivables as of September 30, 2006 and June 30, 2006.

Gross loss for the quarter ended September 30, 2006 reflected a favorable change of approximately $90,000 compared to the quarter ended September 30, 2005. Gross loss for the quarter ended September 30, 2006 as a percentage of revenues decreased from a negative 24.3% for the quarter ended September 30, 2005 to a negative 2.5% in the current quarter. This favorable change was due primarily to higher sales volume.

Research and development expenses were $207,824 for the quarter ended September 30, 2006, compared to $208,111 for the same period last year. While these expenses were virtually unchanged, they reflect a shift from previous activities aimed at the development of new technologies to applications of these technologies for customer-driven product development. Quarterly research and development expenses depend on the Company’s assessment of new product opportunities and available resources.

Selling, general and administrative expenses increased by approximately $78,000, or 18% for the quarter ended September 30, 2006 compared to the same period last year. This was due primarily to a non-cash charge related to stock-based compensation expense following the implementation of SFAS No. 123(R) along with costs associated with enhanced sales and marketing activities focused on increasing sales of recently developed products.
 
16
 
Interest income increased by approximately $6,100, or 66%, for the quarter ended September 30, 2006 compared to the previous year. The increase was due to higher interest rates offset by lower base of cash and cash equivalents.

No income tax provision was recorded in the first quarter of fiscal year 2006 or 2005 because of the losses generated in those periods.

Liquidity and Capital Resources

For the three months ended September 30, 2006, the Company’s cash and cash equivalents decreased by $755,449 to $1,274,979. The decrease in cash was due primarily from cash used in operating activities of $695,172, capital expenditures of $24,481, and patent costs of $39,456.

The Company believes, based on its operating and strategic plans and the cash held by the Company, that it will have sufficient funds to conduct operations through at least the next twelve months. We may need to raise additional capital in the near term to fund our operations, in particular, to support our ongoing product development activities. We may seek funding through additional public or private equity offerings, debt or other strategic financings or agreements with customers or vendors. Additional financing may not be available to us when needed, or, if available, may not be available on favorable terms. If we cannot obtain adequate financing on acceptable terms when such financing is required, our business will be adversely affected.

Contractual cash commitments for the fiscal years subsequent to September 30, 2006 are summarized as follows:

   
2007
  
2008
  
Thereafter
  
Total
  
                   
Operating leases
  
$
24,388
  
$
5,641
  
$
371
  
$
30,400
  

The Company generally provides a standard one-year warranty on materials and workmanship to its customers. The Company provides for estimated warranty costs at the time product revenue is recognized. Warranty costs are included as a component of cost of goods sold in the accompanying consolidated statements of operations. For the three month periods ended September 30, 2006 and 2005, warranty costs were not significant.

Trends and Uncertainties That May Affect Future Results

For the quarter ended September 30, 2006, the Company’s cash and cash equivalents decreased by $755,449, compared to an increase of $1,537,413 for the previous quarter ended June 30, 2006 as a result of the receipt of $2,112,500 in gross proceeds from the closing of a private placement on April 13, 2006.

Capital equipment expenditures during the quarter ended September 30, 2006 were $24,481, up from approximately $8,017 from the same period in 2005. Future capital expenditures will depend on future sales and the success of ongoing research and development efforts.

For the quarter ended September 30, 2006, research and development expenses were $207,824, compared to $208,111 a year earlier. The level of future quarterly R&D expenses will ultimately depend on the Company’s assessment of new product opportunities and available cash resources.
 
17
 
The Company believes that the recent introduction of several new products, along with new and ongoing customer relationships, will generate additional revenues, which are required in order for the Company to achieve profitability. In the coming months the Company will continue to focus its efforts on marketing products recently introduced or redesigned. The Company believes that these marketing activities, if successful, may result in the continuation of its recent pattern of sales growth.

Item 3  Controls and Procedures
 
(a) Our Chief Executive Officer and Chief Financial Officer have evaluated our disclosure controls and procedures and internal control over financial reporting and concluded that our disclosure controls and procedures were not effective as of September 30, 2006 solely because of the following material weakness in internal control over financial reporting with respect to accounting for stock-based compensation: a failure to ensure the correct application of SFAS 123(R) as of its effective date for the Company, July 1, 2006. During its quarterly review, the Company’s independent accountants identified this weakness.
 
We believe that, as of the date of this filing, we have remediated this material weakness in our internal control over financial reporting with respect to accounting for stock-based compensation. The issue related to SFAS 123(R) was detected and corrected prior to the release to the public of the financial results for the quarter ended September 30, 2006. Going forward, the Company has established new procedures requiring the ongoing review and implementation of changes in accounting rules and related disclosure requirements. This will take the form of periodic review meetings between the Company’s Chief Executive Officer and Chief Financial Officer, to be held at least twice per quarter - once at the beginning of each quarter and once prior to each filing with the SEC containing the Company’s financial statements. This policy has been adopted as of this filing.
 
In connection with this Form 10-QSB, our Chief Executive Officer and Chief Financial Officer have evaluated our disclosure controls and procedures as currently in effect, including the remedial actions discussed above and have concluded that, as of this date, our disclosure controls and procedures are effective.
 
(b) There was no change in our internal control over financial reporting during the quarter ended September 30, 2006, that materially affected, or is reasonably likely to materially affect, such internal control over financial reporting. However, subsequent to September 30, 2006, we took the remedial actions described above.
 
 
18

PART II. OTHER INFORMATION
 
Items 1-5  
Not Applicable. 
        
           
Item 6
Exhibits
        
   
 Exhibit
31.1
-
 Certifications of the Company’s Chief Executive Officer required by Rule 13a-14(a)/15d-14(a)
           
   
 Exhibit
31.2
-
 Certification of the Company’s Chief Financial Officer required by Rule 13a-14(a)/15d-14(a)
           
   
 Exhibit
32.1
-
 Certifications of the Company’s Chief Executive Officer and Chief Financial Officer required by Rule 13a-14(b) and 18 U.S. C. 1350.
 
19
 
In accordance with the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     
  PRECISION OPTICS CORPORATION, INC.
 
 		  
 		  
 
Date: November 14, 2006 By:   /s/ Michael T. Pieniazek
 
Michael T. Pieniazek
  Vice President and Chief Financial Officer
 
 
20
 
 
EXHIBIT INDEX


Exhibit 31.1 - Certifications of the Company’s Chief Executive Officer required by Rule 13a-14(a)/15d-14(a)

Exhibit 31.2 - Certification of the Company’s Chief Financial Officer required by Rule 13a-14(a)/15d-14(a)

Exhibit 32.1 - Certifications of the Company’s Chief Executive Officer and Chief Financial Officer required by Rule 13a-14(b) and 18 U.S. C. 1350


21